From targeting the tumor to targeting the immune system: Transversal challenges in oncology with the inhibition of the PD-1/PD-L1 axis

gan Bersanelli, Melissa, Buti, Sebastiano
Cyhoeddwyd yn World J Clin Oncol (2017)

Cabozantinib in metastatic renal cell carcinoma: latest findings and clinical potential

gan Bersanelli, Melissa, Buti, Sebastiano
Cyhoeddwyd yn Ther Adv Med Oncol (2017)

Spotlight on cabozantinib for previously untreated advanced renal cell carcinoma: evidence to date

gan Bersanelli, Melissa, Leonardi, Francesco, Buti, Sebastiano
Cyhoeddwyd yn Cancer Manag Res (2018)

The way towards tailored treatment for metastatic renal cancer patients in the omics era: are we getting a “transcriptomic compass”?

gan Bersanelli, Melissa, Cortellini, Alessio, Buti, Sebastiano
Cyhoeddwyd yn Ann Transl Med (2019)

The interplay between cholesterol (and other metabolic conditions) and immune-checkpoint immunotherapy: shifting the concept from the “inflamed tumor” to the “inflamed patient”...

gan Bersanelli, Melissa, Cortellini, Alessio, Buti, Sebastiano
Cyhoeddwyd yn Hum Vaccin Immunother (2021)

Systemic adjuvant therapies in renal cell carcinoma

gan Buti, Sebastiano, Bersanelli, Melissa, Donini, Maddalena, Ardizzoni, Andrea
Cyhoeddwyd yn Oncol Rev (2012)

Metabolic complete response with vinflunine as second-line therapy in a kidney-transplanted patient with advanced urothelial carcinoma: a case report

gan Bordi, Paola, Tiseo, Marcello, Baldari, Giorgio, Buti, Sebastiano
Cyhoeddwyd yn BMC Cancer (2016)

Everolimus in the management of metastatic renal cell carcinoma: an evidence-based review of its place in therapy

gan Buti, Sebastiano, Leonetti, Alessandro, Dallatomasina, Alice, Bersanelli, Melissa
Cyhoeddwyd yn Core Evid (2016)

Clinical use of lenvatinib in combination with everolimus for the treatment of advanced renal cell carcinoma

gan Leonetti, Alessandro, Leonardi, Francesco, Bersanelli, Melissa, Buti, Sebastiano
Cyhoeddwyd yn Ther Clin Risk Manag (2017)

Family history of cancer and DNA damage response genes: Two sides of the same coin?

gan Cortellini, Alessio, Bersanelli, Melissa, Ficorella, Corrado, Buti, Sebastiano
Cyhoeddwyd yn Thorac Cancer (2018)

Profile of atezolizumab in the treatment of metastatic non-small-cell lung cancer: patient selection and perspectives

gan Facchinetti, Francesco, Bordi, Paola, Leonetti, Alessandro, Buti, Sebastiano, Tiseo, Marcello
Cyhoeddwyd yn Drug Des Devel Ther (2018)

Pathological nodal staging score for renal cell carcinoma: how to build reliable therapeutic choices basing on assumptions

gan Bersanelli, Melissa, Buti, Sebastiano, Santoni, Matteo, Ziglioli, Francesco, Maestroni, Umberto
Cyhoeddwyd yn Ann Transl Med (2019)

Pazopanib as a possible option for the treatment of metastatic non-clear cell renal carcinoma patients: a systematic review

gan Bersanelli, Melissa, Brunelli, Matteo, Gnetti, Letizia, Maestroni, Umberto, Buti, Sebastiano
Cyhoeddwyd yn Ther Adv Med Oncol (2020)

Role of stereotactic body radiation therapy for the management of renal cell carcinoma: tailoring treatment in the era of the “embarrassment of riches”

gan Buti, Sebastiano, Leonetti, Alessandro, Lattanzi, Elisabetta, D’Abbiero, Nunziata, Bersanelli, Melissa
Cyhoeddwyd yn Ann Transl Med (2019)

Feasibility, Safety, and Efficacy of an Alternative Schedule of Sunitinib for the Treatment of Patients with Metastatic Renal Cell Carcinoma: A Retrospective Study

gan Buti, Sebastiano, Donini, Maddalena, Bersanelli, Melissa, Gattara, Alessia, Leonardi, Francesco, Passalacqua, Rodolfo
Cyhoeddwyd yn Drugs R D (2017)

Correction to: Feasibility, Safety, and Efficacy of an Alternative Schedule of Sunitinib for the Treatment of Patients with Metastatic Renal Cell Carcinoma: A Retrospective Study

gan Buti, Sebastiano, Donini, Maddalena, Bersanelli, Melissa, Gattara, Alessia, Leonardi, Francesco, Passalacqua, Rodolfo
Cyhoeddwyd yn Drugs R D (2018)

Gefitinib Plus Interleukin-2 in Advanced Non-Small Cell Lung Cancer Patients Previously Treated with Chemotherapy

gan Bersanelli, Melissa, Buti, Sebastiano, Camisa, Roberta, Brighenti, Matteo, Lazzarelli, Silvia, Mazza, Giancarlo, Passalacqua, Rodolfo
Cyhoeddwyd yn Cancers (Basel) (2014)

Antiangiogenic tyrosine kinase inhibitors and immunotherapy as first-line treatment for metastatic renal cell carcinoma: is there an increased risk of hypothyroidism?

gan Roviello, Giandomenico, Buti, Sebastiano, Cattrini, Carlo, Mennitto, Alessia, Messina, Carlo, Airoldi, Chiara, Vannini, Gianmarco, Bersanelli, Melissa
Cyhoeddwyd yn Ther Adv Urol (2021)

The right immune-modulation at the right time: thymosin α1 for prevention of severe COVID-19 in cancer patients

gan Bersanelli, Melissa, Giannarelli, Diana, Leonetti, Alessandro, Buti, Sebastiano, Tiseo, Marcello, Nouvenne, Antonio, Ticinesi, Andrea, Meschi, Tiziana, Procopio, Giuseppe, Danielli, Riccardo
Cyhoeddwyd yn Future Oncol (2021)

CEA and CYFRA 21-1 as prognostic biomarker and as a tool for treatment monitoring in advanced NSCLC treated with immune checkpoint inhibitors

gan Dall’Olio, Filippo G., Abbati, Francesca, Facchinetti, Francesco, Massucci, Maria, Melotti, Barbara, Squadrilli, Anna, Buti, Sebastiano, Formica, Francesca, Tiseo, Marcello, Ardizzoni, Andrea
Cyhoeddwyd yn Ther Adv Med Oncol (2020)